Merck Maintains Status In Front-Line Cancer Space [Seeking Alpha]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Seeking Alpha
Merck Maintains Status In Front-Line Cancer Space Summary Merck announced FDA approval for Keytruda given in combination with Pfizer's Inlyta to treat front-line advanced kidney cancer patients. FDA Approval for Keytruda along with Inlyta was achieved based on a phase 3 study, where the combination was shown to reduce risk of death by 47% compared to sunitinib. Bristol-Myers Squibb has already received FDA approval for an Opdivo and Yervoy combo in the same population, but is also testing for Opdivo in combination with Exelixis' CABOMETYX. The approval is substantial news, because Keytruda is the first anti-PD-1 as a combination regimen to be approved for these front-line advanced kidney cancer patients. MRK announced that it had received approval FDA Approval Based on Late-Stage Data It's important to note that the FDA approval of Keytruda is in combination with another drug known as Inlyta (axitinib). Inlyta is a drug that was developed and marketed by PFE Keytruda along with Inlyt
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook [Yahoo! Finance]Yahoo! Finance
- Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales [Yahoo! Finance]Yahoo! Finance
- Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]Yahoo! Finance
- TME Pharma Publishes 2023 Financial Results and Provides Operating Update [Yahoo! Finance]Yahoo! Finance
- Merck Lifts Full-Year 2024 Outlook Following First-Quarter Beat [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 4/25/24 - Form 8-K
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- MRK's page on the SEC website